Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM-2121 in Advanced Solid Tumors
NCT07346846Phase 1Recruiting
- Sponsor
- BioGate Precision Medicine
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BGM-2121 in solid tumor, sponsored by BioGate Precision Medicine. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Treatment Discontinuation Due to Drug-Related Adverse Events at 1 year and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
BGM-2121
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07346846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346846.